Business Context and Reporting Period
This Form 8-K was filed by Inpixon (trading symbol: INPX) on December 15, 2023. The report details the entry into material definitive agreements regarding a warrant inducement transaction and the unregistered sale of equity securities. The company is incorporated in Nevada and its common stock is listed on The Nasdaq Capital Market.
Key Financial Metrics and Transaction Details
- Transaction Type: Warrant inducement and private placement of new warrants.
- Warrant Exercise: Holders agreed to exercise 55,000,000 existing warrants.
- Exercise Price Reduction: The exercise price for the 55,000,000 warrants was reduced from $0.10 to $0.0513 per share (a 30% discount to the average closing price).
- Expected Gross Proceeds: The company expects to receive approximately $2,520,427.88 from the exercise of the existing warrants.
- Use of Proceeds: Net proceeds are intended for working capital and general corporate purposes.
- Placement Agent Fees: Joseph Gunnar & Co., LLC was engaged as the exclusive placement agent with a cash fee of 5.5% of gross proceeds and expense reimbursement up to $25,000.
- New Warrants Issued: Holders received new unregistered warrants to purchase shares equal to 100% of the exercised shares (55,000,000 new warrant shares).
- New Warrant Terms: Exercise price of $0.07324 per share (subject to potential reduction to $0.0513); exercisable five years from issuance, contingent on shareholder approval or Nasdaq determination.
Material Changes and Other Events
In addition to the inducement agreements, the company reduced the exercise price for the remaining unexercised existing warrants from $0.10 to $0.07324 per share. This adjustment was made upon receipt of consent from a majority of the then-outstanding existing warrants. The new exercise price for the unexercised warrants equals the average closing price of the common stock for the five trading days prior to the adjustment date.
Guidance, Risks, and Contingencies
- Shareholder Approval: The new warrants are not exercisable until shareholder approval is obtained, unless Nasdaq determines it is not required based on a prior approval obtained on December 8, 2023. A shareholder meeting must be held no later than 90 days after the agreement date if required.
- Registration Rights: The company agreed to file a registration statement (Form S-3 or appropriate form) for the resale of new warrant shares by March 31, 2024, if not already effective, and to keep it effective until no holders own the new warrants.
- Ownership Caps: Holders cannot exercise warrants if the resulting beneficial ownership would exceed 4.99% or 9.99% (at the holder's election) of outstanding shares, unless the cap is adjusted with 61 days' notice.
- Forward-Looking Risks: The filing includes standard disclaimers regarding market conditions, the actual amount of net proceeds, and the ability to maintain Nasdaq listing compliance.
Investor Verification Checklist
- Verify the final net proceeds after deducting the 5.5% placement agent fee and estimated expenses.
- Confirm whether Nasdaq has determined that shareholder approval is required for the exercise of the new warrants.
- Monitor the filing and effectiveness of the registration statement for the resale of new warrant shares by the March 31, 2024 deadline.
- Review the impact of the 55,000,000 share issuance on existing shareholder dilution.
- Check for any subsequent announcements regarding the exercise of the remaining unexercised warrants at the new $0.07324 price.